BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

912 related articles for article (PubMed ID: 21782911)

  • 1. Comparison of HPMC based polymers performance as carriers for manufacture of solid dispersions using the melt extruder.
    Ghosh I; Snyder J; Vippagunta R; Alvine M; Vakil R; Tong WQ; Vippagunta S
    Int J Pharm; 2011 Oct; 419(1-2):12-9. PubMed ID: 21782911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparative study of the effect of spray drying and hot-melt extrusion on the properties of amorphous solid dispersions containing felodipine.
    Mahmah O; Tabbakh R; Kelly A; Paradkar A
    J Pharm Pharmacol; 2014 Feb; 66(2):275-84. PubMed ID: 24433426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced kinetic solubility profiles of indomethacin amorphous solid dispersions in poly(2-hydroxyethyl methacrylate) hydrogels.
    Sun DD; Ju TC; Lee PI
    Eur J Pharm Biopharm; 2012 May; 81(1):149-58. PubMed ID: 22233548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanism of drug release from polymethacrylate-based extrudates and milled strands prepared by hot-melt extrusion.
    Albers J; Alles R; Matthée K; Knop K; Nahrup JS; Kleinebudde P
    Eur J Pharm Biopharm; 2009 Feb; 71(2):387-94. PubMed ID: 18951978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in crystallization rate of nitrendipine enantiomers in amorphous solid dispersions with HPMC and HPMCP.
    Miyazaki T; Aso Y; Yoshioka S; Kawanishi T
    Int J Pharm; 2011 Apr; 407(1-2):111-8. PubMed ID: 21277962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization and stability of solid dispersions based on PEG/polymer blends.
    Bley H; Fussnegger B; Bodmeier R
    Int J Pharm; 2010 May; 390(2):165-73. PubMed ID: 20132875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The utilization of drug-polymer interactions for improving the chemical stability of hot-melt extruded solid dispersions.
    Guo Z; Lu M; Li Y; Pang H; Lin L; Liu X; Wu C
    J Pharm Pharmacol; 2014 Feb; 66(2):285-96. PubMed ID: 24433427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Site specific solubility improvement using solid dispersions of HPMC-AS/HPC SSL--mixtures.
    Zecevic DE; Meier R; Daniels R; Wagner KG
    Eur J Pharm Biopharm; 2014 Jul; 87(2):264-70. PubMed ID: 24768770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Using Flory-Huggins phase diagrams as a pre-formulation tool for the production of amorphous solid dispersions: a comparison between hot-melt extrusion and spray drying.
    Tian Y; Caron V; Jones DS; Healy AM; Andrews GP
    J Pharm Pharmacol; 2014 Feb; 66(2):256-74. PubMed ID: 24192445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Applications of KinetiSol dispersing for the production of plasticizer free amorphous solid dispersions.
    DiNunzio JC; Brough C; Miller DA; Williams RO; McGinity JW
    Eur J Pharm Sci; 2010 Jun; 40(3):179-87. PubMed ID: 20230894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preparation of a solid dispersion of felodipine using a solvent wetting method.
    Kim EJ; Chun MK; Jang JS; Lee IH; Lee KR; Choi HK
    Eur J Pharm Biopharm; 2006 Oct; 64(2):200-5. PubMed ID: 16750355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of surfactants as plasticizers in preparing solid dispersions of poorly soluble API: selection of polymer-surfactant combinations using solubility parameters and testing the processability.
    Ghebremeskel AN; Vemavarapu C; Lodaya M
    Int J Pharm; 2007 Jan; 328(2):119-29. PubMed ID: 16968659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of polymer type on the dissolution profile of amorphous solid dispersions containing felodipine.
    Konno H; Handa T; Alonzo DE; Taylor LS
    Eur J Pharm Biopharm; 2008 Oct; 70(2):493-9. PubMed ID: 18577451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigation of drug-excipient interactions in lapatinib amorphous solid dispersions using solid-state NMR spectroscopy.
    Song Y; Yang X; Chen X; Nie H; Byrn S; Lubach JW
    Mol Pharm; 2015 Mar; 12(3):857-66. PubMed ID: 25585133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Formulation performance and processability window for manufacturing a dual-polymer amorphous solid dispersion via hot-melt extrusion and strand pelletization.
    Hörmann TR; Jäger N; Funke A; Mürb RK; Khinast JG; Paudel A
    Int J Pharm; 2018 Dec; 553(1-2):408-421. PubMed ID: 30326284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of surfactants as plasticizers in preparing solid dispersions of poorly soluble API: stability testing of selected solid dispersions.
    Ghebremeskel AN; Vemavarapu C; Lodaya M
    Pharm Res; 2006 Aug; 23(8):1928-36. PubMed ID: 16871443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of fully amorphous dispersions of a low T(g) drug via co-spray drying with hydrophilic polymers.
    Zhao M; Barker SA; Belton PS; McGregor C; Craig DQ
    Eur J Pharm Biopharm; 2012 Nov; 82(3):572-9. PubMed ID: 22922419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application of mixtures of polymeric carriers for dissolution enhancement of fenofibrate using hot-melt extrusion.
    Kalivoda A; Fischbach M; Kleinebudde P
    Int J Pharm; 2012 Jun; 429(1-2):58-68. PubMed ID: 22440149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of hypromellose acetate succinate (HPMCAS) as a carrier in solid dispersions.
    Tanno F; Nishiyama Y; Kokubo H; Obara S
    Drug Dev Ind Pharm; 2004 Jan; 30(1):9-17. PubMed ID: 15000425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stability-enhanced hot-melt extruded amorphous solid dispersions via combinations of Soluplus® and HPMCAS-HF.
    Alshahrani SM; Lu W; Park JB; Morott JT; Alsulays BB; Majumdar S; Langley N; Kolter K; Gryczke A; Repka MA
    AAPS PharmSciTech; 2015 Aug; 16(4):824-34. PubMed ID: 25567525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 46.